Mark Davis-Lorton, MD
Allergy & Immunology · Tarrytown, NYNPI 1396727665
Payments from drug & device makers
Across 695 payments — averaging $525.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Shire North American Group Inc$172K
- Pharming Healthcare, Inc.$75K
- AstraZeneca$34K
- Takeda Pharmaceuticals U.S.A., Inc.$31K
- Biocryst US Sales Co., LLC$29K
- Biocryst Pharmaceuticals, Inc.$9K
- plus $16K from 28 others
What the payments were for
- Consulting fees$68,93833%
- Speaking & faculty fees$114,19355%
- Travel & lodging$6,5573%
- Food & beverage$15,8318%
- Education$5240%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Shire North American Group Inc | 35 | $171,584 |
| Pharming Healthcare, Inc. | 95 | $74,633 |
| AstraZeneca | 80 | $33,520 |
| Takeda Pharmaceuticals U.S.A., Inc. | 66 | $30,704 |
| Biocryst US Sales Co., LLC | 70 | $29,230 |
| Biocryst Pharmaceuticals, Inc. | 14 | $9,092 |
| CSL Behring | 70 | $8,960 |
| Sanofi | 58 | $3,284 |
| Optinose US, Inc. | 51 | $1,011 |
| GSK | 51 | $615 |
| Regeneron Healthcare Solutions, Inc. | 23 | $493 |
| Novartis | 21 | $370 |
| Sanofi-aventis U.S. LLC | 3 | $270 |
| Pfizer | 10 | $182 |
| Incyte Corporation | 4 | $178 |
| Ionis Pharmaceuticals, Inc. | 2 | $136 |
| Genentech USA, Inc. | 6 | $108 |
| Alk-abello, Inc | 5 | $101 |
| Kaleo, Inc. | 5 | $91 |
| Hikma Pharmaceuticals USA | 4 | $77 |
| Stryker | 3 | $75 |
| Boehringer Ingelheim | 3 | $56 |
| Neurent Medical Limited | 2 | $54 |
| Medtronic | 2 | $45 |
| Smith+Nephew | 2 | $44 |
| Amgen(2 entities) | 2 | $40 |
| Precigen, Inc. | 1 | $34 |
| Lilly USA, LLC | 1 | $26 |
| Intersect ENT, Inc. | 1 | $24 |
| Bio Products Laboratory USA, Inc. | 1 | $24 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $23 |
| Paratek Pharmaceuticals, Inc. | 1 | $23 |
| Merck | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$365,136 in reported general payments places this provider in the 95th percentile of 320 allergy & immunology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TakhzyroLanadelumab-Flyo | 50 | $1,920,820 |
| Dupixent PenDupilumab | 40 | $169,598 |
| Dupixent SyringeDupilumab | 24 | $87,391 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 89 | $60,126 |
| XolairOmalizumab | 11 | $28,751 |
| Cromolyn Sodium | 15 | $17,041 |
| Breo ElliptaFluticasone/Vilanterol | 30 | $13,548 |
| SymbicortBudesonide/Formoterol Fumarate | 26 | $8,385 |
| Azelastine Hcl | 249 | $6,625 |
| DuleraMometasone/Formoterol | 17 | $5,495 |
| Arnuity ElliptaFluticasone Furoate | 25 | $5,481 |
| Epinephrine | 20 | $4,874 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 21 | $3,494 |
| Fluticasone Propionate | 169 | $2,235 |
| Levocetirizine Dihydrochloride | 92 | $1,264 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Takhzyro | $30,704 | $1,920,82050 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $615 | $79,155144 claims |
| AstraZenecaSymbicort | $33,520 | $8,38526 claims |
| MerckDulera | $16 | $5,49517 claims |
| Hikma Pharmaceuticals USAEpinephrine | $77 | $4,87420 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 320 allergy & immunology providers in New York.
Other allergy & immunology in Tarrytown
- Peter DeaneRochester$3.7M
- Syed MustafaRochester$3.6M
- Golda HudesBronx$2.4M
- Arye RubinsteinBronx$1.1M
- Ujwala KazaNew York$1.1M
- Robert SporterNew York$980K
- Mili ShumWest Harrison$924K
- Paula BusseNew York$821K
- Gregory PuglisiPlainview$813K
- Stanley GoldsteinRockville Centre$653K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.